
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Anthony El-Khoueiry, MD, provides insight on the case of a 69-year-old man with stage 4 hepatocellular carcinoma and evaluates current and emerging treatment options.
Case: A 69-Year-Old Man with Stage 4 Hepatocellular Carcinoma
Initial presentation
Clinical workup
Treatment and Follow-Up






